Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function in adults with chronic hypoparathyroidism treated with TransCon PTH (palopegteriparatide). The data were shared in an oral presentation on May 12 by Peter Schwarz, M.D., Professor of Clinical Medicine at the University of Copenhagen, during the European Congress of Endocrinology 2024 (ECE 2024), the annual meeting of the European Society of Endocrinology.
Ascendis Pharma A/S（纳斯达克股票代码：ASND）今天公布了对该公司3期Pathway试验的事后分析的2年业绩，该结果表明，接受TransCon PTH（palopegteriparatide）治疗的慢性甲状旁腺功能减退的成年人的肾功能明显持续改善。哥本哈根大学临床医学教授彼得·施瓦兹医学博士在欧洲内分泌学会年会2024年欧洲内分泌学大会（ECE 2024）期间于5月12日的口头陈述中分享了这些数据。